Abstract

Background: With increasing incidence and mortality, cancer is the leading cause of death in China and is a major public health problem. From 2003 to 2010, the incidence and mortality of ovarian cancer maintained a stable trend in China, but due to the large population, the new cases and deaths of ovarian cancer remain high. In 2015, approximately 52,100 women in China were diagnosed with ovarian cancer, and about 22,500 women died of ovarian cancer.

Abstract

Background: Cancer Differentiation Analysis liquid biopsy (CDA) has been investigated as a viable clinical utility in NSCLC diagnosis, as well as a new candidate for part of an overall post-CT scan clinical diagnostic and treatment decision tool kit. It has been also evaluated in NSCLC diagnosis, combined with imaging technologies.

Abstract

Background: For esophageal cancer, no viable non-invasive detection technologies are available today. In earlier investigations, Cancer Differentiation Analysis (CDA) Technology which measures information relating to both protein fragments and cellular signals in blood samples in a single test has showed a significant advantage in esophageal cancer diagnosis.

Abstract

Background: Currently endoscopy examination takes an important role in the diagnosis of colorectal cancer, and there are no other clinically viable noninvasive diagnostic methods.  In this investigation, a newly developed, novel IVD cancer diagnostic technology named Cancer Differentiation Analysis (CDA) Technology was investigated for colorectal cancer diagnosis.  CDA is a new technology using multi-level and multi-parameter information which measures information relating to both protein fragments and cellular signals in blood samples in one single test.

Abstract

BackgroundThe diagnostic accuracy of Cancer Differentiation Analysis (CDA) Technology has beenevaluated and verified in previous studies (Abstract No. e12578, e22171, e12587, and e15059). The aim of this study is to investigate the potential capability of CDA technology for breast cancer prognosis.

Abstract

Background: A newly developed in-vitro diagnostic technology named Cancer Differentiation Analysis Technology (CDA) was investigated for breast cancer screening. The CDA technology is a blood-sample based, multi-level, multi-parameter diagnostic method which detects signals from both proteins and cells, in which multiple aspects and parameters of information were collected to improve diagnostic accuracy.